Logo image of TMDX

TRANSMEDICS GROUP INC (TMDX) Stock Price, Forecast & Analysis

USA - NASDAQ:TMDX - US89377M1099 - Common Stock

131.54 USD
-4.25 (-3.13%)
Last: 10/31/2025, 8:16:33 PM
130.62 USD
-0.92 (-0.7%)
After Hours: 10/31/2025, 8:16:33 PM

TMDX Key Statistics, Chart & Performance

Key Statistics
Market Cap4.48B
Revenue(TTM)441.54M
Net Income(TTM)71.66M
Shares34.09M
Float33.08M
52 Week High145.5
52 Week Low55
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)2.47
PE53.26
Fwd PE46.92
Earnings (Next)02-25 2026-02-25/amc
IPO2019-05-02
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


TMDX short term performance overview.The bars show the price performance of TMDX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40

TMDX long term performance overview.The bars show the price performance of TMDX in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200 250

The current stock price of TMDX is 131.54 USD. In the past month the price increased by 13.7%. In the past year, price increased by 59.64%.

TRANSMEDICS GROUP INC / TMDX Daily stock chart

TMDX Latest News, Press Relases and Analysis

TMDX Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 24.77 215.16B
ISRG INTUITIVE SURGICAL INC 62.05 191.53B
BSX BOSTON SCIENTIFIC CORP 34.14 149.24B
SYK STRYKER CORP 27.05 136.19B
MDT MEDTRONIC PLC 16.4 116.34B
BDX BECTON DICKINSON AND CO 12.52 51.22B
IDXX IDEXX LABORATORIES INC 52.42 50.36B
EW EDWARDS LIFESCIENCES CORP 32.08 48.41B
RMD RESMED INC 24.94 36.03B
GEHC GE HEALTHCARE TECHNOLOGY 16.33 34.22B
PHG KONINKLIJKE PHILIPS NVR- NY 16.46 26.31B
STE STERIS PLC 24.71 23.21B

About TMDX

Company Profile

TMDX logo image TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Company Info

TRANSMEDICS GROUP INC

200 Minuteman Road

Andover MASSACHUSETTS 01810 US

CEO: Waleed H. Hassanein

Employees: 728

TMDX Company Website

TMDX Investor Relations

Phone: 19785520900

TRANSMEDICS GROUP INC / TMDX FAQ

Can you describe the business of TRANSMEDICS GROUP INC?

TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.


What is the current price of TMDX stock?

The current stock price of TMDX is 131.54 USD. The price decreased by -3.13% in the last trading session.


Does TRANSMEDICS GROUP INC pay dividends?

TMDX does not pay a dividend.


What is the ChartMill rating of TRANSMEDICS GROUP INC stock?

TMDX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Where is TRANSMEDICS GROUP INC (TMDX) stock traded?

TMDX stock is listed on the Nasdaq exchange.


Can you provide the PE ratio for TMDX stock?

The PE ratio for TRANSMEDICS GROUP INC (TMDX) is 53.26. This is based on the reported non-GAAP earnings per share of 2.47 and the current share price of 131.54 USD.


What is the market capitalization of TMDX stock?

TRANSMEDICS GROUP INC (TMDX) has a market capitalization of 4.48B USD. This makes TMDX a Mid Cap stock.


TMDX Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to TMDX. When comparing the yearly performance of all stocks, TMDX is one of the better performing stocks in the market, outperforming 87.18% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TMDX Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to TMDX. TMDX has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TMDX Financial Highlights

Over the last trailing twelve months TMDX reported a non-GAAP Earnings per Share(EPS) of 2.47. The EPS increased by 162.77% compared to the year before.


Industry RankSector Rank
PM (TTM) 13.49%
ROA 8.05%
ROE 22.53%
Debt/Equity 1.61
Chartmill High Growth Momentum
EPS Q2Q%450%
Sales Q2Q%32.23%
EPS 1Y (TTM)162.77%
Revenue 1Y (TTM)82.74%

TMDX Forecast & Estimates

18 analysts have analysed TMDX and the average price target is 149.33 USD. This implies a price increase of 13.52% is expected in the next year compared to the current price of 131.54.

For the next year, analysts expect an EPS growth of 138.61% and a revenue growth 39.65% for TMDX


Analysts
Analysts81.11
Price Target149.33 (13.52%)
EPS Next Y138.61%
Revenue Next Year39.65%

TMDX Ownership

Ownership
Inst Owners111.43%
Ins Owners2.96%
Short Float %24.1%
Short Ratio8.85